Health Tech Hiring Remains 'Brutal'
Despite advances in AI, the demand for consultative sales talent in healthcare tech remains acute. A recent analysis calls the hiring environment 'brutal', noting that talent scarcity can elongate sales cycles, especially for companies trying to displace incumbents or expand into new territories.
The U.S. healthcare revenue cycle management (RCM) market was valued at approximately $140 billion in 2023 and is projected to continue growing by double digits. This expansion is fueled by healthcare providers adopting AI and automation to fight rising claim denials and billing complexity. Selling into this market involves navigating a notoriously long sales cycle, now averaging between 125 and 153 days. More than half of B2B professionals report that sales cycles have gotten longer, partly because the average buying committee now involves 6.3 stakeholders, up from previous years. A primary hurdle for new entrants is "vendor lock-in" with dominant Electronic Health Record (EHR) systems like Epic and Meditech. These established platforms create closed ecosystems, making it difficult for providers to adopt more innovative or specialized solutions without facing significant integration challenges and costs. This environment intensifies the need for sales professionals who can act as true consultants. With legacy systems causing high staff burnout due to manual tasks and operational inefficiencies, the sales conversation must focus on demonstrating tangible ROI and workflow improvements to multiple decision-makers, from finance to clinical leads. While AI is a major trend, it's not replacing the sales role but augmenting it. AI-powered tools are being deployed to automate administrative tasks like scheduling and follow-ups, allowing sales reps to focus on high-value activities such as building relationships and strategizing complex deals. Despite these challenges, significant capital is flowing into the sector. Healthtech startups raised $15.3 billion in 2025, a 26.1% increase from 2024. Investors are specifically targeting companies that automate clinical workflows and improve the revenue cycle, signaling a strong market appetite for displacing less efficient incumbents.
